Cardiovascular Research

Erectile dysfunction in the cardiac patient.

Authors: Robert A Kloner

Affiliations: + Expand

Abstract

Erectile dysfunction (ED) often is caused by endothelial dysfunction and may be a sign that a patient has vascular disease elsewhere in the body. Risk factors for coronary artery disease such as lipid abnormalities, smoking, diabetes, and hypertension also are risk factors for ED. Oral therapy for ED, such as sildenafil, inhibits phosphodiesterase-5 (PDE-5) and the breakdown of cyclic guanosine monophosphate. PDE-5 inhibitors have been shown to be safe and effective for the therapy for ED, but remain contraindicated in patients receiving organic nitrates. These agents are mild vasodilators and are being investigated for their treatment potential for patients with pulmonary hypertension, heart failure, and endothelial dysfunction.

---

Chemical List

Antihypertensive Agents|||Phosphodiesterase Inhibitors|||Piperazines|||Purines|||Sulfones|||Sildenafil Citrate|||Phosphoric Diester Hydrolases|||3',5'-Cyclic-GMP Phosphodiesterases|||Cyclic Nucleotide Phosphodiesterases, Type 5|||PDE5A protein, human

---

Reference List

Urology. 2001 Sep;58(3):441-5|||Am J Epidemiol. 1994 Nov 15;140(10):930-7|||Am J Cardiol. 1999 Mar 4;83(5A):21C-28C|||BMJ. 2001 Mar 17;322(7287):651-2|||Am J Hypertens. 2001 Jan;14(1):70-3|||Am J Cardiol. 2002 Jun 1;89(11):1331-4|||J Urol. 1996 May;155(5):1795-800|||Curr Atheroscler Rep. 2002 Sep;4(5):397-401|||Prev Med. 2000 Apr;30(4):328-38|||Diabetes Care. 2002 Aug;25(8):1336-9|||J Clin Invest. 1990 Jul;86(1):228-34|||Am J Cardiol. 2003 Nov 6;92(9A):47M-57M|||JAMA. 2002 Feb 13;287(6):719-25|||Am J Hypertens. 2001 Jan;14(1):27-31|||J Hypertens. 2000 Dec;18(12):1865-9|||Am J Cardiol. 1999 Mar 4;83(5A):35C-44C|||Am J Cardiol. 2000 Jul 15;86(2):175-81|||Urology. 2002 Sep;60(2 Suppl 2):67-90|||JAMA. 1996 May 8;275(18):1405-9|||Circulation. 2001 Sep 11;104(11):1218-22|||N Engl J Med. 1990 Jul 5;323(1):22-7|||Circulation. 1996 Aug 1;94(3):258-65|||Am J Physiol. 1996 Apr;270(4 Pt 2):H1435-40|||J Urol. 2003 Aug;170(2 Pt 2):S46-50; discussion S50|||Am J Cardiol. 1999 Mar 4;83(5A):29C-34C|||Am J Cardiol. 1999 Feb 15;83(4):576-82, A7|||N Engl J Med. 1998 May 14;338(20):1397-404|||Circulation. 2002 May 21;105(20):2398-403|||Lancet. 2002 Sep 21;360(9337):895-900|||J Am Coll Cardiol. 2000 Sep;36(3):845-51|||Circulation. 2002 Aug 27;106(9):1097-103|||J Urol. 1994 Jan;151(1):54-61|||Diabetes Care. 1996 Feb;19(2):135-41|||N Engl J Med. 1995 Feb 23;332(8):481-7|||Lancet. 1985 Jan 26;1(8422):181-4|||J Am Coll Cardiol. 1999 Jan;33(1):273-82|||J Am Coll Cardiol. 2002 Dec 4;40(11):2006-12|||Am J Cardiol. 2002 Sep 15;90(6):677-80|||N Engl J Med. 2000 Jun 1;342(22):1622-6